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Abstract
Background: Mantle Cell Lymphoma (MCL) is often associated with progression, temporary response to therapy
and a high relapse rate over time resulting in a poor long-term prognosis. Because MCL is classified as an incurable
disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying
resistance associated with MCL therapies and about associated predictors remains poor. The REFRACT-LYMA Cohort, a
multicenter prospective cohort of patients with MCL, is set up to address this limitation. We here describe the study
background, design and methods used for this cohort.
Methods/Design: The REFRACT-LYMA Cohort Study aims at including all patients (>18 years old) who are diagnosed
with MCL in any stage of the disease and treated in specialized oncology centers in three public hospitals in
Northwestern France. Any such patient providing a signed informed consent is included. All subjects are followed up
indefinitely, until refusal to participate in the study, emigration or death. The REFRACT-LYMA follow-up is continuous
and collects data on socio-economic status, medical status, MCL therapies and associated events (resistance, side
effects). Participants also complete standardized quality of life (QOL) questionnaires. In addition, participants are asked
to donate blood samples that will support ex vivo analysis of expression and functional assays required to uncover
predictive biomarkers and companion diagnostics. If diagnostic biopsies are performed during the course of the
disease, extracted biological samples are kept in a dedicated biobank.
Discussion: To our knowledge, the REFRACT-LYMA Cohort Study is the first prospective cohort of patients with MCL
for whom “real-life” medical, epidemiological and QOL data is repeatedly collected together with biological samples
during the course of the disease. The integrative cohort at mid-term will be unique at producing a large variety
of data that can be used to conceive the most effective personalized therapy for MCL patients. Additionally, the
REFRACT-LYMA Cohort puts the medical care of MCL patients in a health and pharmacoeconomic perspective.
Keywords: Cancer, Mantle cell lymphoma, Cohort, Therapeutic failure, Biological samples, Functional assays,
Quality of life, Epidemiology, Pharmacoeconomics
Background
Mantle Cell Lymphoma (MCL) is a Non-Hodgkin
lymphoma (NHL) defined as a unique type of B-cell
lymphoma entity [1]. MCL accounts for approximately
5–10 % of all NHLs. Its incidence is estimated at around
0.5 per 100,000 person/year [2, 3]. Patients are generally
Caucasian, male and elderly [2]. Some data suggests that
MCL incidence may vary geographically and may pos-
sibly have increased over the last decades [2]. While
some NHLs have been found to be related to specific
inherited, environmental or infectious exposures, no
strong and consistent relationship has been established
for MCL [2, 4]. There are indeed but few studies of
potential risk factors, often retrospective and primarily
conducted by pooling all NHLs. However, it has been
suggested that MCL might be associated with exposure
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to Borrelia burgdoferi [5] and with family history of
hematopoietic malignancies and of genetic variation in
the pro-inflammatory cytokine interleukin 10 [6, 7]. All
these findings must be confirmed and remain controver-
sial. Large prospective studies with sufficient statistical
power and data quality are needed to confirm/discover
risk factors associated with MCL.
MCL is usually diagnosed as a late-stage disease that has
typically spread to the gastrointestinal tract and bone mar-
row [8]. MCL is often associated with temporary response
to therapy, varying from months to decades, and the high
relapse rate over time results in a poor long-term progno-
sis [9]. Overall survival (OS) is heterogeneous with a
reported median around 5 years [3, 10]. An efficient prog-
nostic index has been developed to predict OS: the Mantle
Cell Lymphoma International Prognostic Index (MIPI)
[11]. It classifies patients into three risk groups: low, inter-
mediate and high risk. However, as emphasized elsewhere
[4], the MIPI is prognostic for survival, not for therapeutic
decisions and has been only validated for first-line therapy.
Additional research is needed to identify associated risk
factors and develop appropriate prognostic scores for
all these situations.
Because MCL is classified as an incurable disease,
therapeutic resistance is of great interest. In MCL, thera-
peutic resistance may schematically be divided in two
categories: 1) primary resistance (the disease does not
respond to the therapeutic agent(s) because of intrinsic
characteristics and/or of a protective environment) and 2)
acquired resistance (the disease was sensitive but relapse
occurs as one or several resistant subclones emerge, that
initially were in minority or that were acquired through
therapeutic pressure) [12]. The Darwinian selective pres-
sure and associated biological mechanisms still need to be
clarified. This is crucial in order to decide whether to
establish a therapy and/or to extend it or not. Biobanks of
tumor samples, collected in a standardized manner before
launching new therapies and at potential therapeutic
failures, are required to achieve these goals.
Furthermore, MCL therapies have a huge economic
impact on society. Temsirolimus, the first drug to re-
ceive EMA approval, costs £36,000 per year [13]. Esti-
mates say that an Ibrutinib therapy (70 % of respondent
patients in monotherapy) costs $110,000 per year in the
United States [14]. It is strategic to identify predictors
of response/sensitivity to therapies precisely. This would
not only spare patients unnecessary therapies, but also
optimize healthcare resources and reduce unnecessary
costs. The issue is reinforced by growing availability
of other promising molecules, e.g. ABT-199 (GDC-
199), BTK/PI3K inhibitors or new antibodies [15–18].
Possessing a cohort of MCL patients is a strategic
asset for the pharmacoeconomic evaluation of associated
therapies.
Finally, Quality of life (QOL) is recognized by clini-
cians and researchers to be an important indicator for
cancer patients, both in clinical management and for the
cost-benefit evaluation of therapies. Various studies of
the impact of QOL on hematological cancers and associ-
ated therapies [19] have been performed. There have
been fewer studies of NHL and even less of MCL. A
recent study shows that QOL should be assessed at diag-
nosis and used as prognostic factor in patients with
aggressive lymphoma [20]. Some studies focus on the
QOL of long-term survivors of non-Hodgkin lymphoma
[21]. Measuring QOL is necessary to get an integrative
vision of MCL and to improve clinical management.
To address all these limitations, we have developed a
multicenter prospective cohort of patients with MCL:
the REFRACT-LYMA Cohort.
Study objectives
The goals of the REFRACT-LYMA Cohort Study are:
 To improve the characterization of MCL
epidemiology (incidence, temporal trends,
geographical disparities, risk factors, nature of
treatments, duration of response to each sequential
line of treatment)
 To understand the biological mechanisms that
precipitate the occurrence of severe side effects,
response or resistance associated to MCL therapies
 To identify new therapeutic targets for the MCL
treatment
 To determine the clinical, biological and quality of
life impacts of MCL therapies
 To evaluate the temporal dynamic of patient
response to therapies
 To identify patient characteristics affecting primary
resistance development or severe side effects
associated with MCL therapies
 To find and optimize the most effective therapeutic
associations in MCL treatment
 To construct reliable prognostic scores predicting
response to MCL therapies
 To conduct pharmaco-economic evaluations of
MCL therapies
 To develop evidence-based therapeutic algorithms
based on biological characteristics of a patient's
tumor
 To further basic research in the field of MCL
The focus of this report is describing the methodology
used to establish and manage this cohort.
This program is based on a network that includes the
Medical university of Nantes, the INSERM_U892
CNRS_U6299 research unit (Cancer Research Center
Nantes-Angers, Nantes), the Nantes university Hospital
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and the General Hospitals in La Roche sur Yon and in
Vannes. All centers follow the same treatment guideline.
Fit untreated patients below the age of 70y are treated
with a cytarabine-based plus rituximab chemotherapy
regimen followed by autologous stem cell transplant-
ation and rituximab maintenance, while elderly or unfit
patients receive R-CHOP plus Rituximab maintenance.
According to various paraeters (duration of response,
age, fit/unfit..), patients are commonly treated with a
bendamustine-based chemotherapy regimen. Allogeneic-
stem cell transplantation is discussed for refractory young
patients. Ibrutinib is offered to relapse refractory patients
and inclusion in clinical trials can also be proposed.
Design
Study design
The REFRACT-LYMA Study is an observational cohort
study that aims at including all patients diagnosed with
MCL followed in specialized oncology centers within
three public hospitals in Northwestern France (Nantes
University Hospital and the General Hospitals in La
Roche sur Yon and in Vannes) over at least a 10-year
period. All newly diagnosed patients are followed pro-
spectively. Patients already dealt with in study sites at
study start are followed prospectively, from their inclu-
sion and onwards. For these patients, previous clinical
data is recorded retrospectively from medical files. The
cohort is registered by the French Data Protection
Authority in clinical research (Commission Nationale de
l’Informatique et des Libertés or CNIL). The study was
approved by an ethics committee (Groupe Nantais
d'Ethique dans le Domaine de la Santé, RC14_0358).
Study population
Adult men and women (>18 years old) diagnosed with
MCL according to the 2008 World Health Organization
classification of lymphoid neoplasms [1] in any stage of
the disease at any of the three study hospitals are eligible
for the study. The study excludes non French-speaking
patients with no social insurance and patients with de-
mentia or mental conditions that prevent them from
completing the surveys correctly. The physicians recruit
the patients. Once they have been informed that par-
ticipating is voluntary and anonymous, all patients who
give informed consent are included. The study physi-
cians ask all participants if they have properly under-
stood the study.
Data collection
The REFRACT-LYMA study is based on a continuous
and comprehensive record of pre-specified and stan-
dardized information on all included patients.
Specific data is compiled at baseline plus at each
follow-up visit, according to the reason for follow-up. In
the REFRACT-LYMA Cohort Study, the reason for
follow-up is categorized as follows: disease diagnostic,
disease progression, disease relapse, treatment initiation,
treatment monitoring, treatment toxicity, end of treat-
ment and monitoring in absence of treatment. As the
study is non-interventional, each study physician follows
included patients as well as possible according to their
clinical, biological, psychological and social situation.
Subjects are followed indefinitely until secondary refusal
to take part in the study, emigration or death. Save for a
significant event (therapeutic failure, adverse events…),
the three study hospitals will usually follow up patients
every 6 months.
Follow-up is continuous. It includes collecting data on
socioeconomic and medical status plus on MCL therap-
ies and associated events (resistance and side effects).
The participants also complete standardized quality of
life questionnaires. The participants are additionally
asked to give a blood sample at baseline and at specific
follow-up stages. For any diagnostic biopsy performed
during the course of the disease (e.g. bone marrow,
lymph node, pleural effusion, cerebrospinal fluid), ex-
tracted biological samples will also be kept in a dedicated
biobank. Table 1 shows the collected data according to
reason for follow-up throughout the study.
Sociodemographic and epidemiological data
Sociodemographic and epidemiological characteristics
are assessed by means of standardized questionnaires
managed by the physicians. They cover demographics
(birth year, sex, education, profession, living situation,
place of residence, ethnicity, number of children and,
when applicable, date and associated cause of death),
body weight, height, physical activities, smoking and al-
cohol habits, family and personal history of lymphoma
and others types of cancer and of constitutive or acquired
immunodeficiency. This questionnaire is completed at
baseline and follow-up. Time-varying sociodemographic
and epidemiological data is updated every year.
Medical and therapeutic data
The Eastern Cooperative Oncology Group (ECOG) Per-
formance Status [22] and disease status (complete remis-
sion/stable disease/partial response) are systematically
assessed at follow-up. The International Prognostic
Index (IPI) [23] and MIPI [11] calculation results are
calculated. The treatment initiation date, treatment type,
response to treatment and date of response are recorded
for each administrated treatment.
The REFRACT-LYMA Cohort also collects the Ann
Arbor staging (I, II, III, IV), the presence/absence of
splenomegaly, a digestive expression of lymphoma and
circulating tumor cells, the number of extranodal terri-
tories, the serum lactate dehydrogenase and creatinine
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Table 1 Collected data throughout the REFRACT-LYMA cohort study























Place of residencea X
Ethnicity X
Number of childrena X
Death informationa
Epidemiological data
Body weight and heighta X
Physical activitiesa X
Smoking and alcohol habitsa X
Family history of cancer X





ECOG performance status X X X X X X X X
Disease status X X X X X X X X
Ann Arbor staging X X X X X
IPI X X X X X
MIPI X X X X X
Splenomegaly X X X X X
Digestive expression of lymphoma X X X X X
Circulating tumor cells X X X X X
Number of extranodal territories X X X X X
Serum lactate dehydrogenase level X X X X X
Creatinine level X X X X X
Hemoglobin concentration X X X X X
White blood cell count X X X X X
Bone marrow biopsy data X X X X X
Tumor cell cytological morphology X X X X X
Molecular markers X X X X X
Genetic abnormality: t(11,14) and del17 X X X X X
B-cell and MCL markers X X X X X
Monoclonality X X X X X
MRD X X X X X X
PET data X X X X X
Adverse events X X X X X X X X
Treatment data
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levels, the hemoglobin concentration and the white
blood cell count, as needed for the IPI [23] and the MIPI
[11] calculation.
Anatomological and genetic characteristics are
assessed with data from a bone marrow biopsy with as-
sociated results (absence/presence of bone marrow le-
sions). Tumor cells are classified into classic or variant
types (blastoid variant and polymorphic variant) accord-
ing to cytologic morphology. Information on specific
molecular markers and on t(11,14) genetic translocation
or del17 genetic deletion is recorded. Quantitative data
on expressions of B-cell and MCL markers and on the
Minimal Residual Disease (MRD) is collected. If positron
emission topography (PET) is used during follow-up, the
date, place and associated standardized uptake values
are registered.
Adverse event data
All adverse events with date of occurrence are recorded
in the database. The classification used to describe the
severity of organ toxicity for patients receiving cancer
therapy [24] is based on the Common Terminology Cri-
teria for Adverse Events (CTCAE) V3.0 from the Na-
tional Cancer Institute (NCI) of the National Institutes
of Health (NIH). Toxicity is graded as mild (Grade 1),
moderate (Grade 2), severe (Grade 3) or life-threatening
(Grade 4), with specific parameters according to the
organ system involved. Death (Grade 5) is used for some
criteria to point out fatality. In this shared terminology,
adverse event means any abnormal clinical finding tem-
porally associated with the use of a therapy. The causal-
ity is not required.
Comorbidity
Comorbidity is recorded with the Cumulative Illness
Rating Scale for Geriatrics (CIRS-G) [25]. This scoring
system addresses 14 organ systems (vascular problems,
hematopoietic system, respiratory tract, liver, gallbladder,
pancreas, endocrine and metabolic disease, breast, heart,
musculoskeletal/integumentary, lower gastrointestinal
tract, eyes, ears, nose, throat, genitourinary tract, upper
gastrointestinal tract, neurological disease, renal disorder
and psychiatric disorder). For each patient, comorbidity
is associated with an organ system and rated from one
(mild comorbidity) to four (extremely severe comorbid-
ity). If more than one disease occur in the same organ
system, only the most severe is rated. If a disease can be
traced back to the primary disorder (the reason for
hospitalization), it is not recorded as comorbidity. This
questionnaire is completed at baseline and follow-up.
Associated data is updated every year.
Quality of life
Three measures are used to assess quality of life in
patients with Mantle cell lymphoma at baseline and
follow-up.
First, the Medical Outcomes Study Short Form (SF-
36) survey, a general physical and mental health meas-
ure, is used for comparison with general population
norms. It covers 36 items organized into eight subscales
and two summary scores, the Physical Component Score
(PCS; Physical Functioning, Role-Physical, Bodily Pain
and General Health) and Mental Component Score
(MCS; Vitality, Social Functioning, Role-Emotional and
Mental Health) [26].
Second, the EuroQOL five dimensions survey (EQ-
5D) facilitates pharmacoeconomic evaluation. It is a
standardized instrument measuring health-related quality
of life and applicable to a wide range of health condi-
tions and treatments [27]. It is a simple questionnaire
with five questions and a visual analogue scale (EQ-
VAS). EQ-5D is primarily designed for self-completion
by respondents and ideally suited for postal surveys, in
clinics or during face-to-face interviews. It has been
developed and validated in many countries, including
France.
Table 1 Collected data throughout the REFRACT-LYMA cohort study (Continued)
Treatment characteristics X X X X X X
Comorbidity
CIRS-Ga X
Quality of life X X X X X X X X
Biological samples and functional assays
Biological samples: blood sample, bone
marrow, lymph node, pleural effusion,
cerebrospinal fluid
X X X X X X
Flow cytometry X X X X X X
RNA analysis: X X X X X X
Functional assays X X X X X X
aData updated every year
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Third, the Functional Assessment of Chronic Illness
Therapy - Lymphoma (FACT-Lym) is used to capture
lymphoma-specific QOL [28]. This short, adequately val-
idated QOL measure consists of a general module
(FACT-G), four subscales (physical, social/family, emo-
tional and functional) and a 15-item lymphoma specific
module listing lymphoma-related symptoms (e.g. fever,
night sweats, itching).
Biological samples and functional assays
Blood samples are collected from the patients upon re-
cruitment and at specific follow-up appointments
(Table 1). For each blood sample and immediately after
blood draw, specific biomarkers are assessed by flow
cytometry. In addition to classical analysis related to
medical data, cytokine receptors such as CD210 (IL10R),
CD221 (IGF1R), CD126 (IL6R), CD360 (IL21R), CD268
(BAFFR), extracellular markers such as CD38, CD40,
CD138, and viability (Annexin-V) are addressed. After
purification using MACS CD19 MicroBeads (Miltenyi
Biotec), the percentage of MCL tumor cells exceeds 90 %,
measured by flow cytometry. Some purified cells are
stored as dry pellets for further RNA, DNA or protein
analysis, others are used for functional assays. RNA
analysis includes systematic PCR quantification of
genes previously described as related to chemoresis-
tance such as Bcl-2, Mcl-1, Bcl-xL or Bim (BCL2L11)
(ref 18). Several markers of MCL aggressive behavior,
e.g. Ki67 and Sox11 [29], are also determined. We will
also assess the integrity of the p53 pathway, chromo-
somal deletion and/or somatic mutations that have
been reported as prognosis markers [30].
Ex vivo functional assays and correlation with targeted
therapy response are matched with expression analysis, to
develop predictive biomarkers and companion diagnostics.
In addition to response at the cellular level, targeted ther-
apy efficacy are matched at the mitochondrial level using
functional BH3-profiling [31].
There is growing evidence suggesting a critical role of
microenvironment in MCL [32]. Cell cycle, survival, mi-
gration and chemoresistance of MCL primary cells are
addressed in various relevant coculture models (mesen-
chymal stromal, lymphoid, myeloid) in presence of MCL
specific growth factors. This strategy will document the
so far unknown bidirectional communications between
MCL primary cells and their surrounding ecosystem. Fi-
nally, the main results will be validated in vivo, using
relevant mouse models [33].
Remaining blood samples are stored in a unique
biobank at −80 °C that is hosted by the INSERM_U892
CNRS_U6299 research unit (CRCNA, Nantes). They
will be used later for functional assays and for gene
and biomarker analysis. When possible, biopsies from
lymph nodes, bone marrow and pleural effusion are
analyzed using the same protocol as for the blood
samples.
Data management
This multicenter study relies on a web-based system
with data being entered into a central database. The sys-
tem provides security with a protected access and com-
plies with French safety policy. For each new patient
included and associated follow-up, data is collected on
paper forms and entered into the web-based data entry
portal by the project workers and the medical team. The
data management team performs a data quality control
every year. The local medical team is notified in case of
discrepancy or incomplete data.
Sample size and statistical analysis
In this study, the number of patients coming to the three
study hospitals to consult for MCL per year determines
the cohort size. All patients accepting to participate are
included. Altogether around 50 patients diagnosed with
MCL are taken in by the three study oncology centers
every year. Roughly half of these are new. Based on the
study physicians’ experience, 10 % of patients refuse to
participate or don’t meet the inclusion criteria. A final
sample size of around 240 patients is thus expected for a
study period of 10 years including interim analyses per-
formed at 3 and 5 years.
Confidence intervals, means, standard deviations and
frequency distributions are calculated for all measures.
Corrections for multiple comparisons are used to con-
trol the occurrence of type I statistical errors. All ana-
lyses are performed with R [34]. Kaplan-Meier survival
curves are used to compare follow-up data. Logistic re-
gression or Cox regression adjusts for patient character-
istics and is used for survival analysis for different
groups of patients. Depending on the statistical power
available, various advanced statistical models are used.
Discussion
To our knowledge, this is the first prospective cohort of
patients with MCL where medical, epidemiological and
QOL data is repeatedly collected in combination with
biological samples collected before treatment initiation
and at treatment failure. Recruitment is expected to start
by January 2016. In the mid-term, this integrative cohort
will be a unique data source enabling each MCL patient
to conceive the most effective personal therapy accord-
ing to a large variety of data (patient tumor biological
characteristics, epidemiological data, patient medical his-
tory, QOL measures and ex-vivo functional assays).
Additionally, the REFRACT-LYMA Cohort will answer
health and pharmacoeconomic questions about the med-
ical care of MCL patients using “real-life data”, as op-
posed to clinical trials. However, larger studies may be
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necessary for these areas to be investigated in depth and
to allow for solid and reproducible conclusions. That is
why the REFRACT-LYMA Cohort uses standardized
data, facilitating future collaborative data pooling as far
as possible. The REFRACT-LYMA Cohort is also designed
to facilitate collaboration with investigators, institutions,
cooperative groups and pharmaceutical companies work-
ing in the MCL area.
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